+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06790082

Evaluating FAPI PETCT Imaging for Diagnosis and Treatment Assessment in Pleural Mesothelioma

Led by Aalborg University Hospital · Updated on 2026-11-02

70

Participants Needed

1

Research Sites

521 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new imaging technique called Gallium-68 labelled fibroblast activation protein inhibitor FAPI PETCT to improve diagnosis and staging of pleural mesothelioma PM, a type of cancer affecting the lining of the lungs. This prospective phase 2 study will enroll 70 patients suspected of having PM who are referred for pleural biopsy. The goal is to compare the accuracy of FAPI PETCT with conventional imaging methods, including FDG PETCT, using tissue biopsy as the reference standard. The study will also explore how well FAPI PETCT can assess treatment response in patients undergoing chemotherapy or immunotherapy. Participants will receive an additional FAPI PETCT scan at initial cancer staging within four weeks of their standard FDG PETCT and before biopsy. Those who proceed with anticancer treatments will have further FAPI PETCT and FDG PETCT scans after completing 2-3 treatment cycles to evaluate changes. The study procedures are extra to routine care and will not affect patient management, with results kept blinded from patients and doctors. Throughout the study, patients will undergo imaging tests and diagnostic procedures as part of regular care, with added FAPI PETCT scans for research purposes. Researchers will monitor diagnostic performance, staging accuracy, biopsy locations, uptake values, and treatment response over periods ranging from 2 to 10 years. Safety of the FAPI tracer and long-term outcomes like survival and disease progression will also be evaluated. The study will last until 2037, with extensive follow-up planned.

CONDITIONS

Brief Title

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma

Research Team

M

Morten Bentestuen, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here